# EDGAR Filing Document

**Accession Number:** 0001819133
**File Stem:** 0001193125-25-311209
**Filing Date:** 2025-12
**Character Count:** 2560
**Document Hash:** 502a995f55150dbf15dfe41532f01ae3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-311209.hdr.sgml**: 20260403

**ACCESSION NUMBER**: 0001193125-25-311209

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tango Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001819133
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (857) 320-4900

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 901
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BCTG Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200723

**<u>VIA EDGAR</u>**

December 8, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jimmy McNamara

**Re: Tango Therapeutics, Inc.** 

**Acceleration Request for Registration Statement on Form S-3**

**File No. 333-291683** 

Dear Mr. McNamara,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Tango Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to December 10, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Sarah Ashfaq at (212) 459-7238.

If you have any questions regarding this request, please contact Sarah Ashfaq of Goodwin Procter LLP at (212) 459-7238.

---

| |
|:---|
|  Sincerely, |
| TANGO THERAPEUTICS, INC. |
| /s/ Barbara Weber |
|  Barbara Weber |
|  Chief Executive Officer and President |

---

cc: Daniella Beckman, *Tango Therapeutics, Inc.*

Julie Fogarty, *Tango Therapeutics, Inc.*

Mitchell S. Bloom, Esq., *Goodwin Procter LLP*